Universal reference book for medicines
Composition, form of production and packaging
Liofilizate for the preparation of a solution for intravenous administration
in the form of a mass from white to light yellow color.

1 f.

phospholipids (C 100 lipoid) 500 mg

sodium glycyrrhizinate (trisodium salt of glycyrrhizic acid) 200 mg

2.5 g - glass bottles (5) complete with water and water solvents (amp 10 ml 5 pcs.) - plastic contour packings (1) - cardboard packs.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2016.

PHARMACHOLOGIC EFFECT

Combined drug.

Has a membrane-stabilizing, hepatoprotective and antiviral effect.

Phosphatidylcholine (the main component of phospholipids) is the main structural element of cellular and intracellular membranes, capable of restoring their structure and functions in damage, providing a cytoprotective effect.
Normalizes protein and lipid metabolism, prevents the loss of hepatocytes of enzymes and other active substances, restores the detoxifying function of the liver, inhibits the formation of connective tissue, reducing the risk of fibrosis and cirrhosis of the liver.
Glycyrrhizic acid has an anti-inflammatory effect, suppresses the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis, increasing the activity of natural killer cells.
Has a hepatoprotective effect due to antioxidant and membrane-stabilizing activity. Potentiates the action of endogenous glucocorticoids, providing anti-inflammatory and anti-allergic effects in non-infectious liver lesions.
When the skin is damaged due to the membrane-stabilizing and anti-inflammatory effect of the components, it limits the spread of the process and promotes regression of the disease.

INDICATIONS

- viral hepatitis (acute and chronic);

- fatty liver degeneration (hepatosis);

- other liver damage (medicinal, alcoholic, toxic);

- cirrhosis of the liver;

- intoxication;

- psoriasis;

- Neurodermatitis;

- Eczema.

DOSING MODE

Adults and children over 12 years: in / in, pre-dissolving the powder in 10 ml of water for injection.
I / O administration should be slow. Enter 10 ml daily 2 times / day in the morning and in the evening for 10 days with the subsequent transition to oral administration of the drug in the form of capsules. The duration of the course can be increased on the recommendation of a doctor.
SIDE EFFECT

From the skin and subcutaneous tissues: with increased individual sensitivity, a skin rash may appear, which disappears after the drug is discontinued.

When the daily dose is exceeded: sodium and fluid retention, edema, increased blood pressure, hypokalemia are possible.
If these symptoms appear, depending on their severity, it is necessary to reduce the dose of the drug and / or to prescribe spironolactone at 50-100 mg / day.
CONTRAINDICATIONS

- Pregnancy;

- the period of lactation (breastfeeding);

- children's age till 12 years;

- Hypersensitivity to the components of the drug.

PREGNANCY AND LACTATION

The drug is contraindicated for use in pregnancy and lactation (breastfeeding).

APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS

Caution should be given to patients with portal hypertension.

APPLICATION FOR CHILDREN

Contraindication: children under 12 years.

DRUG INTERACTION

The contents of the vial should not be mixed with other solutions.

For dissolution use only water for injection.

Do not use saline solution of sodium chloride or glucose solution for dilution.

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored out of the reach of children, protected from light at a temperature of no higher than 20 ° C.
Term - 2 years. Product name: PHOSPHOGLIV® FORTE (PHOSPHOGLIV FORTE)

Active substance: glycyrrhizinic acid, non welcome

Type: Hepatoprotector with immunomodulating and antiviral action

Manufacturer: ФАРМСТАНСТАНАР-ЛЕКСРЕДСТВА (Russia)
Composition, form of production and packaging
Capsules
hard gelatinous, №0, with the case and a cover of brown color;
the content of the capsules is an oil paste-like mass from light yellow to orange-brown in color, with a weak specific odor.
1 caps.

phospholipids (lipoid PPL-400) 400 mg,

in terms of the main component - phosphatidylcholine 73-79% 300 mg

sodium glycyrrhizinate (trisodium salt of glycyrrhizic acid) 65 mg

10 pieces.
- Packings contour mesh (5) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2016.

PHARMACHOLOGIC EFFECT

Combined drug.

Has a membrane-stabilizing, hepatoprotective and antiviral effect.

Phosphatidylcholine (the main component of phospholipids) is the main structural element of cellular and intracellular membranes, capable of restoring their structure and functions in damage, providing a cytoprotective effect.

Normalizes protein and lipid metabolism, prevents the loss of hepatocytes of enzymes and other active substances, restores the detoxification function of the liver, inhibits the formation of connective tissue, reducing the risk of fibrosis and cirrhosis.

Glycyrate (glycyrrhizic acid and salts) has an anti-inflammatory effect, suppresses the reproduction of viruses in the liver and other organs by stimulating the production of interferons, enhancing phagocytosis, increasing the activity of natural killer cells.
Has a hepatoprotective effect due to antioxidant and membrane-stabilizing activity. Potentiates the effect of endogenous glucocorticosteroids, providing anti-inflammatory and anti-allergic effects in non-infectious liver lesions.
When the skin is damaged due to the membrane-stabilizing and anti-inflammatory effect of the components, it limits the spread of the process and promotes regression of the disease.

PHARMACOKINETICS

The components of the drug are absorbed well in the intestine, both in the form of the whole molecule and the bioactive products of their hydrolysis (unsaturated fatty acids, choline, glycyrrhetic acid), which after absorption through the intestinal walls easily penetrate the liver, lungs, skin and other organs.

INDICATIONS

- viral hepatitis (acute and chronic);

- fatty liver degeneration (hepatosis);

- medicinal, alcoholic, toxic liver damage;

- cirrhosis of the liver;

- intoxication;

- psoriasis;

- Neurodermatitis;

- Eczema.

DOSING MODE

The drug is taken orally, with food.
Capsules should be washed down with a small amount of liquid.
Adults appoint 1-2 caps.
3 times / day, children over 12 years - 1 caps. 3 times / day.
SIDE EFFECT

Dermatological reactions: skin rash, which disappears after drug withdrawal (with increased individual sensitivity).

Rarely , when daily doses are exceeded, sodium and liquid retention may occur, which is manifested by peripheral edema and increased blood pressure, hypokalemia.

CONTRAINDICATIONS

- Pregnancy;

- lactation period;

- children's age till 12 years;

- Hypersensitivity to the components of the drug.

PREGNANCY AND LACTATION

The drug is contraindicated for use in pregnancy and lactation.

APPLICATION FOR CHILDREN

Contraindication: children under 12 years.

SPECIAL INSTRUCTIONS

When there is a delay in sodium and fluid and hypokalemia, depending on their severity, it is necessary to reduce the dose of the drug and / or to prescribe spironolactone at 50-100 mg / day.

OVERDOSE

There were no cases of drug overdose Phosphogliv ® forte.

DRUG INTERACTION

Drug interaction of the preparation Phosphogliv ® forte is not described.

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored out of reach of children at a temperature of no higher than 25 ° C.
Shelf life - 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!